– USA, CA – CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced the addition of four key hires to their growing leadership team.
- Josh Held becomes an independent new board member,
- Michael Redard will serve as CURE’s Chief Financial Officer.
- Bhaumik Patel is CURE’s director of new technologies
- Teresa Virgallito will be a scientific advisor.
Patel, Virgallito and Held join CURE as a result of its recent acquisition of Chemistry Holdings Inc., a formulation technology company, in an all-stock transaction.
“The expertise and in-depth experience from this new crop of hires within this industry are unmatched,” says Rob Davidson, CEO of CURE Pharmaceutical. “Our team is growing at a fast-pace and this trusted team of experts are bound to lead us to new heights as we continue to develop solutions to improve drug delivery.”
Redard joins CURE with over 30 years of experience in financial operations, strategic planning, and capital markets. His career has spanned a broad range of industries, including medical devices, healthcare, consumer products, and manufacturing. Prior to CURE, Redard held CFO, vice president and general manager positions with several venture capital and private equity-backed companies, including Inogen, Medical Analysis Systems, CDTi Advanced Materials, and Abrisa Technologies. He has a B.S. in business administration from California Polytechnic State University, San Luis Obispo.
Held is a third-generation entrepreneur whose diverse expertise spans finance, law, sales, and marketing. A forward-thinking innovator, he has broad experience in corporate development, deal origination, complex deal structures, legal planning, business succession planning, new brand build-outs, media planning, and cross-disciplinary leadership. He was founder and CEO of Chemistry Holdings, a formulation technology company that created innovative, sustainable delivery systems for a variety of industries. Josh is also the founder and CEO of Made by Science, which is at the forefront of the creation of next-generation delivery systems for cannabis product manufacturers and sellers.
Patel is an expert in drug encapsulation and has developed dosage forms such as tablets, soft gel, and hard-shell capsules, pharmaceutical suspensions and semisolids. Prior to joining CURE, he served as a senior scientist group lead at Chemistry Holdings, Inc. He holds a Master of Science with a specialization in industrial pharmacy from Long Island University.
Virgallito has specialized in physical and mechanical encapsulation, ingredient engineering, food law regulations and food safety, microbiology and chemical instrumentation. Before CURE, Virgallito was the EVP of Chemistry Holdings, Inc. She has developed drug delivery and formulation solutions for Procter & Gamble, Kraft, Unilever, Cargill, the U.S. Army, and the U.S. Navy.
About CURE Pharmaceutical
CURE Pharmaceutical is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and patient experience through its proprietary drug dosage forms and delivery systems. CURE has a full-service cGMP manufacturing facility and is a pioneering developer and manufacturer of a patented and proprietary delivery system, one of the most advanced oral thin film on the market today. CURE is developing an array of products in innovative delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, and Israel. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information: https://www.curepharmaceutical.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
